Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study

NCT00439725 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1197

Enrollment

INDUSTRY

Sponsor class

Conditions

Venous Thromboembolism

Interventions

DRUG: Rivaroxaban (Xarelto, BAY59-7939)
DRUG: Placebo

Sponsor

Bayer

Collaborators

[object Object]